{
  "docId": "019de072-122c-721c-8b62-3522a74ffc66",
  "docSlug": "bcca0cb7dade19d9f637477238714c68",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 33,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a vertical icon-based process flow to connect clinical facts to the conclusion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-122c-721c-8b62-3522a74ffc66/17",
  "deckHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66",
  "deckJsonHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66.json",
  "deckAnchorHref": "/decks/019de072-122c-721c-8b62-3522a74ffc66#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.17,
        "x": 0.11,
        "y": 0.22
      },
      "kind": "image",
      "text": "Vertical chain of icons representing disease progression",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7de5924c-b667-4f2c-8d75-4513b05e2abf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.63,
        "x": 0.33,
        "y": 0.25
      },
      "kind": "list",
      "text": "ARG1-D is a progressive, debilitating, metabolic disease characterized by high levels arginine. In its classic presentation, three major manifestations begin in early childhood: spasticity, seizures, and intellectual disability. Delays in diagnosis are common, leading to disease progression and worse clinical outcomes. Burden on patients and caregivers is high, and most patients lose the ability to walk independently. Only treatment is severe dietary protein restriction, which commonly does not reduce arginine levels to current goal of <200 µmol/L. New and effective therapies are needed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d7ddfdf-f7d9-4765-9bff-a7ae85738f65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.73,
        "x": 0.26,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Carvalho DR, et al. Gene. 2012;509:124–130. 2. Carvalho DR, et al. Pediatr Neurol. 2012;46:369–374. 3. Amayreh W, et al. Dev Med Child Neurol. 2014;56:1021–1024. 4. Bakhiet M, et al. Medicine (Baltimore). 2018;97:e10780. 5. Huemer M, et al. J Inherit Metab Dis. 2016;39:331–340. 6. Haberle J, et al. Orphanet J Rare Dis. 2012;7:32.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f35f6f39-ba66-4782-a7d1-0b1c27cc99e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.78,
        "x": 0.11,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARG1-D is a Debilitating Metabolic Disease that Severely Impairs Patients' Quality of Life",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8373153-cfaa-405c-82fa-8bc43d00f87c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "8d49c3b4-2853-406c-9358-e8358c175d4c",
      "evidence": "ARG1-D is a progressive, debilitating, metabolic disease characterized by high levels arginine.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 17,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ea540d90-0192-4c0c-aee8-a16c8ad598b1",
      "evidence": "The deck highlights the debilitating effects of ARG1-D on patients' quality of life",
      "position": 0,
      "objective": "Highlight the cost of inaction for patients with ARG1-D",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}